KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Change in Receivables (2016 - 2025)

Rigel Pharmaceuticals has reported Change in Receivables over the past 11 years, most recently at $5.8 million for Q4 2025.

  • Quarterly results put Change in Receivables at $5.8 million for Q4 2025, down 47.12% from a year ago — trailing twelve months through Dec 2025 was $10.1 million (down 8.29% YoY), and the annual figure for FY2025 was $10.1 million, down 8.29%.
  • Change in Receivables for Q4 2025 was $5.8 million at Rigel Pharmaceuticals, down from $6.0 million in the prior quarter.
  • Over the last five years, Change in Receivables for RIGL hit a ceiling of $126.2 million in Q1 2021 and a floor of -$124.8 million in Q2 2021.
  • Median Change in Receivables over the past 5 years was $936500.0 (2021), compared with a mean of $1.8 million.
  • Peak annual rise in Change in Receivables hit 28087.14% in 2021, while the deepest fall reached 6138.85% in 2021.
  • Rigel Pharmaceuticals' Change in Receivables stood at $481000.0 in 2021, then skyrocketed by 5054.89% to $24.8 million in 2022, then crashed by 71.75% to $7.0 million in 2023, then skyrocketed by 57.62% to $11.0 million in 2024, then crashed by 47.12% to $5.8 million in 2025.
  • The last three reported values for Change in Receivables were $5.8 million (Q4 2025), $6.0 million (Q3 2025), and -$1.6 million (Q2 2025) per Business Quant data.